Our goal in Nov 2018:
Provectus has begun work in support of extended 12-week administration (proof-of-concept or POC) for topically applied, non-steroidal PH-10:
We are committed to properly monetizing this important asset for shareholders by developing PH-10 into a Phase 3-ready candidate, for both psoriasis and atopic dermatitis, in an efficient, effective, and industry-recognized manner.”
Our goal in May 2021 (from 10Q, Page 16):
The Company’s strategy is to (i) demonstrate 12-week single-agent administration proof-of-concept (“POC”) for topical PH-10 that includes (a) a preclinical safety study of extended 12-week administration (compared to, previously, four weeks), (b) a clinical mechanism of action study in atopic dermatitis
Our goal for this POC work is to achieve Phase 3 trial-ready status for topical PH-10 in both psoriasis and atopic dermatitis.
Any guess for 2022 and 2023 goals (if company still exist at that time) ?
Judas goat aka LTG and sheep will call me basher if I post this kind of information. But if I post PH-10 is worth Billions of dollars and BP interested in product and its just matter of time then I get 10 recommendations and I am pro PVCT.